219 related articles for article (PubMed ID: 14609760)
1. [Allorecognition of the recipient after hematopoietic transplantation].
Tiberghien P; Robinet E; Ferrand C; Saas P; Hervé P
Bull Cancer; 2003; 90(8-9):706-10. PubMed ID: 14609760
[TBL] [Abstract][Full Text] [Related]
2. Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.
Chao NJ
Biol Blood Marrow Transplant; 2004 Apr; 10(4):215-23. PubMed ID: 15077220
[TBL] [Abstract][Full Text] [Related]
3. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
4. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
6. Minor antigen solves major problem.
Dazzi F; Simpson E; Goldman JM
Nat Med; 2001 Jul; 7(7):769-70. PubMed ID: 11433332
[No Abstract] [Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.
Natzke AM; Shaw JL; McKeller MR; Emo KL; Mullen CA
Biol Blood Marrow Transplant; 2007 Jan; 13(1):34-45. PubMed ID: 17222751
[TBL] [Abstract][Full Text] [Related]
9. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
[TBL] [Abstract][Full Text] [Related]
10. [Graft vs. host disease and graft vs. leukemia/tumor effect].
Okamoto S
Nihon Rinsho; 2003 Sep; 61(9):1484-7. PubMed ID: 14515713
[No Abstract] [Full Text] [Related]
11. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia.
Falkenburg JH; Willemze R
Best Pract Res Clin Haematol; 2004 Sep; 17(3):415-25. PubMed ID: 15498713
[TBL] [Abstract][Full Text] [Related]
12. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease.
Fontaine P; Roy-Proulx G; Knafo L; Baron C; Roy DC; Perreault C
Nat Med; 2001 Jul; 7(7):789-94. PubMed ID: 11433342
[TBL] [Abstract][Full Text] [Related]
13. Adoptive transfer of allogeneic antigen-specific T cells.
Riddell SR; Bleakley M; Nishida T; Berger C; Warren EH
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):9-12. PubMed ID: 16399578
[TBL] [Abstract][Full Text] [Related]
14. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
15. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies.
Zeiser R; Marks R; Bertz H; Finke J
Ann Hematol; 2004 Sep; 83(9):551-65. PubMed ID: 15449032
[TBL] [Abstract][Full Text] [Related]
16. T cell immunity and graft-versus-host disease (GVHD).
Ichiki Y; Bowlus CL; Shimoda S; Ishibashi H; Vierling JM; Gershwin ME
Autoimmun Rev; 2006 Jan; 5(1):1-9. PubMed ID: 16338205
[TBL] [Abstract][Full Text] [Related]
17. T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation.
Schetelig J; Kiani A; Schmitz M; Ehninger G; Bornhäuser M
Cancer Immunol Immunother; 2005 Nov; 54(11):1043-58. PubMed ID: 15887014
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients.
Boeck S; Hamann M; Pihusch V; Heller T; Diem H; Rolf B; Pihusch R; Kolb HJ; Pihusch M
Bone Marrow Transplant; 2006 Jan; 37(1):57-64. PubMed ID: 16258529
[TBL] [Abstract][Full Text] [Related]
19. Minor histocompatibility antigens: targets for tumour therapy and transplant tolerance.
Spierings E
Int J Immunogenet; 2008 Aug; 35(4-5):363-6. PubMed ID: 18976439
[TBL] [Abstract][Full Text] [Related]
20. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.
Hartwig UF; Nonn M; Khan S; Link I; Huber C; Herr W
Biol Blood Marrow Transplant; 2008 Jan; 14(1):99-109. PubMed ID: 18158966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
